CN112739361B - Use of laminarin for preparing medicine for preventing or treating sarcopenia - Google Patents
Use of laminarin for preparing medicine for preventing or treating sarcopenia Download PDFInfo
- Publication number
- CN112739361B CN112739361B CN201980061359.0A CN201980061359A CN112739361B CN 112739361 B CN112739361 B CN 112739361B CN 201980061359 A CN201980061359 A CN 201980061359A CN 112739361 B CN112739361 B CN 112739361B
- Authority
- CN
- China
- Prior art keywords
- present
- sarcopenia
- laminarin
- myostatin
- preventing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000001076 sarcopenia Diseases 0.000 title claims abstract description 31
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 title claims description 17
- 229920001543 Laminarin Polymers 0.000 title claims description 17
- 239000005717 Laminarin Substances 0.000 title claims description 17
- 239000003814 drug Substances 0.000 title claims description 5
- 238000011282 treatment Methods 0.000 claims description 11
- 238000002360 preparation method Methods 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 2
- 239000000284 extract Substances 0.000 abstract description 25
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 16
- 239000004480 active ingredient Substances 0.000 abstract description 14
- 239000000203 mixture Substances 0.000 abstract description 14
- 235000013305 food Nutrition 0.000 abstract description 9
- 102000004472 Myostatin Human genes 0.000 description 26
- 108010056852 Myostatin Proteins 0.000 description 26
- 230000014509 gene expression Effects 0.000 description 24
- 229920000855 Fucoidan Polymers 0.000 description 15
- 210000003205 muscle Anatomy 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 102100025014 E3 ubiquitin-protein ligase TRIM63 Human genes 0.000 description 11
- 101710164910 E3 ubiquitin-protein ligase TRIM63 Proteins 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 11
- 108010006654 Bleomycin Proteins 0.000 description 10
- 241000047339 Salicornia brachystachya Species 0.000 description 10
- 229960001561 bleomycin Drugs 0.000 description 10
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 235000018102 proteins Nutrition 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 238000007911 parenteral administration Methods 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000004925 denaturation Methods 0.000 description 4
- 230000036425 denaturation Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 210000002027 skeletal muscle Anatomy 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000722731 Carex Species 0.000 description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 208000029578 Muscle disease Diseases 0.000 description 2
- 241000199919 Phaeophyceae Species 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 238000011530 RNeasy Mini Kit Methods 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 239000003263 anabolic agent Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000000137 annealing Methods 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 101150107963 eno gene Proteins 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 210000003130 muscle precursor cell Anatomy 0.000 description 2
- -1 peanut oil Chemical compound 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 239000000849 selective androgen receptor modulator Substances 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 238000012795 verification Methods 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- 208000030090 Acute Disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 241000219357 Cactaceae Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241000871189 Chenopodiaceae Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 240000003421 Dianthus chinensis Species 0.000 description 1
- 102000016970 Follistatin Human genes 0.000 description 1
- 108010014612 Follistatin Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- 206010028311 Muscle hypertrophy Diseases 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241000634212 Penia Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010093965 Polymyxin B Proteins 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 244000294611 Punica granatum Species 0.000 description 1
- 235000014360 Punica granatum Nutrition 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 206010047486 Virilism Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 229960003942 amphotericin b Drugs 0.000 description 1
- 229940070021 anabolic steroids Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003972 antineoplastic antibiotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 239000001913 cellulose Chemical class 0.000 description 1
- 229920002678 cellulose Chemical class 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 230000012042 muscle hypertrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 210000003098 myoblast Anatomy 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000024 polymyxin B Polymers 0.000 description 1
- 229960005266 polymyxin b Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229960002847 prasterone Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical class CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 208000026455 prostate symptom Diseases 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 239000013535 sea water Substances 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 210000002363 skeletal muscle cell Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/21—Amaranthaceae (Amaranth family), e.g. pigweed, rockwort or globe amaranth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/316—Foods, ingredients or supplements having a functional effect on health having an effect on regeneration or building of ligaments or muscles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Botany (AREA)
- Polymers & Plastics (AREA)
- Physical Education & Sports Medicine (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Food Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
According to an embodiment of the present invention, there are provided a pharmaceutical composition for preventing or treating sarcopenia comprising an extract of turfgrass as an active ingredient, and a food composition for preventing or improving sarcopenia comprising an extract of turfgrass as an active ingredient.
Description
Technical Field
The present invention relates to a pharmaceutical composition for preventing or treating sarcopenia, comprising an extract of salicornia herbacea as an active ingredient.
Background
The concept of sarcopenia began with the "sarcopenia syndrome" (sarcopenia) proposed by Irwin Rosenberg in 1989, which was derived from greek, a combination of "sarco" meaning muscle and "penia" meaning reduction. Sarcopenia is associated with aging and refers to a reduction in muscle strength due to a reduction in muscle mass. Here, "muscle (muscle)" refers to skeletal muscle (skeletal muscle), and is independent of smooth muscle (smooth muscle). That is, sarcopenia mainly refers to loss of skeletal muscle mass distributed in four limbs, which is distinguished from muscle atrophy (primary muscle disease) caused by acute diseases such as cachexia (advanced malignant tumor, a significant muscle loss state), influenza, and the like, or primary muscle disease.
With the rapid increase in age groups of older people over 65 years of age, the prevalence of osteoporosis and sarcopenia has also increased rapidly. It is known that a gradual decrease in muscle mass occurs in the 40 year old population until the 70 year old population decreases 8% every 10 years, after which even faster rates of decrease, up to 15% every 10 years, can occur. Many follow-up studies have shown that the physiological changes occurring in the elderly are diverse, and generally, muscle mass and bone density decrease with age.
In addition, there are three main treatments for sarcopenia. First, move. Exercise has been reported to improve the protein synthesis ability of skeletal muscle in a short period of time, and to increase the muscle strength or activity ability of the elderly. But this is not suitable for long-term treatment. Second, testosterone (Testosterone) or anabolic steroids (anabolic steroid) can be used as a drug therapy, but this leads to virilization in women, while prostate symptoms (prostates symptomatoms) and other side effects in men. Other approved prescriptions include Dehydroepiandrosterone (DHEA) and growth hormone, and studies have shown that DHEA can be used as a therapeutic approach in areas including Selective Androgen Receptor Modulators (SARMs). Furthermore, diet is also considered a treatment, but nutritional assessment indicates that malnutrition or modern dietary habits are not suitable for maintaining adequate total body weight.
Myostatin (myostatin) is a polypeptide growth factor belonging to the TGF- β superfamily. TGF- β has a large number of isoforms (isofomm) known to be associated with cell proliferation (proliferation), apoptosis (apoptosis), differentiation, bone formation and maintenance (Massague & Chen, 2000). Among them, myostatin belongs to Growth Differentiation Factor (GDF) 8, which participates in growth and development of tissues and acts by activating Smad signaling system. In addition, it has been reported that the p21 gene inhibits cell cycle and proliferation of precursor cells, thereby affecting formation and regeneration of bone. Myostatin is produced mainly in skeletal muscle cells, causing muscle loss and sarcopenia in an autocrine manner, and is thought to inhibit protein synthesis and cell proliferation in myoblasts by inhibiting the expression of IGF-1 or follistatin associated with muscle hypertrophy.
In addition, the turfgrass grass grows to about 10 to 30cm high with the branches facing each other. The stem is initially dark green or yellow and then turns red in autumn and is as thick and fleshy as a small cactus. Later the leaves degenerate almost invisible and have small film-like scales. Three flowers bloom in the upper segment of the branch in august to september. The stamens have plump meat, 1-2 stamens and 2 stigmas. The fruit is pomegranate, which is wrapped in the peel and has black seeds. It is an annual herbaceous plant that grows in groups near tidal beaches where seawater flows into inland salt ponds. In the korean medical field, it is considered to eliminate toxins accumulated in the body and constipation and to have excellent therapeutic effects on various incurable diseases such as cancer, hysteromyoma, sinusitis, hypertension, hypotension, back pain, diabetes, bronchial asthma, hypothyroidism, hyperthyroidism, skin diseases, arthritis, etc.
Disclosure of Invention
Technical problem to be solved
Under such circumstances, the present inventors have made an effort to find a substance capable of treating sarcopenia by inhibiting the expression of myostatin, which causes muscle loss and sarcopenia, and found that a turfgrass salt component can be used for preventing or treating sarcopenia by inhibiting the production of myostatin protein and the increase in mRNA expression, thereby completing the present invention.
The present invention aims to provide a pharmaceutical composition for preventing or treating sarcopenia, comprising an extract of salicornia herbacea as an active ingredient.
Another object of the present invention relates to a food composition for preventing or improving sarcopenia, comprising the extract of salicornia herbacea as an active ingredient.
However, the problems to be solved by the present invention are not limited to the above-mentioned problems, and other problems not mentioned can be clearly understood by those skilled in the art from the following description.
Means for solving the problems
According to an embodiment of the present invention, there is provided a pharmaceutical composition for preventing or treating sarcopenia, comprising an extract of salicornia herbacea as an active ingredient.
According to one aspect, the turfgrass salt horn extract comprises laminarin (laminarin) or fucoidan (fucoidan).
According to one aspect, the pharmaceutical composition may inhibit expression of myostatin (myostatin) mRNA or protein.
According to one aspect, bleomycin (bleomycin) causes expression of the myostatin (myostatin) mRNA or protein.
According to one side, UV may cause the expression of myostatin mRNA or protein.
According to one aspect, the pharmaceutical composition can inhibit the expression of MURF1 (Muscle RING-finger protein-1) mRNA or protein.
According to another embodiment of the present invention, there may be provided a food composition for preventing or improving sarcopenia, comprising an extract of salicornia herbacea as an active ingredient.
ADVANTAGEOUS EFFECTS OF INVENTION
The pharmaceutical composition for preventing or treating sarcopenia, which contains the turfgrass alternifolia extract as an active ingredient, of the present invention inhibits the production of myostatin protein and the increase of mRNA expression, which directly affect muscle loss and sarcopenia, and can play a more thorough role in preventing or treating sarcopenia.
However, the effects of the present invention are not limited to the above-described effects, and should be understood to include all effects that can be derived from the detailed description of the present invention or the configuration of the present invention described in the claims.
Drawings
FIG. 1 is a graph showing the effect of inhibiting the expression of myostatin by UV when laminarin and fucoidan are used for treatment.
FIG. 2 is a graph showing the effect of bleomycin-induced inhibition of myostatin expression when treated with laminarin and fucoidan.
FIG. 3 is a graph showing the effect of UV-induced inhibition of MURF1 (Muscle RING-finger protein-1) protein expression in laminarin and fucoidan treatments.
Detailed Description
Hereinafter, embodiments of the present invention will be described in detail with reference to the drawings. Various modifications may be made to the following examples, and thus the scope of the claims of the present application is not limited or restricted by the following examples. All modifications, equivalents and alternatives to all embodiments are intended to be included within the scope of the claims.
The terminology used in the examples is for the purpose of describing particular embodiments only and is not intended to be limiting of embodiments. Where not otherwise stated in the context, singular expressions include plural meanings. In the present specification, the terms "comprising" or "having" are used to express that there are the features, numerals, steps, operations, constituent elements, components or combinations thereof described in the specification, and do not exclude that there are one or more other features, numerals, steps, operations, constituent elements, components or combinations thereof, or additional functions.
All terms used herein, including technical or scientific terms, have the ordinary meaning as understood by one of ordinary skill in the art without further definition. The terms commonly used in the art, which are commonly defined as dictionary definitions, should be understood as meanings consistent with the common contents of the related art, and should not be over-idealized or formally construed without explicit mention in this application.
In the description with reference to the drawings, the same constituent elements are denoted by the same reference numerals regardless of the reference numerals, and redundant description thereof will be omitted. In describing the embodiments, when it is judged that a detailed description of the related well-known art may unnecessarily obscure the embodiments, a detailed description thereof will be omitted.
According to an embodiment of the present invention, there is provided a pharmaceutical composition for preventing or treating sarcopenia, comprising an extract of salicornia herbacea as an active ingredient.
In the present invention, the term "Salicornia herbacea extract (Salicornia herbacea)" is a medicinal name of Korean medicine, and refers to halophytes (halophytes) belonging to the family Chenopodiaceae of the order Dianthus.
In the present invention, the term "extract" includes an extract obtained by extracting a plant, a diluted or concentrated solution of the extract, a dried product obtained by drying the extract, a preparation or a purified product of the extract or a mixture thereof, an extract itself, and extracts of all preparations that can be formed using the extract. The turfgrass salt carex extract of the present invention can be preferably prepared and used in the form of dry powder after extraction. In addition, the turfgrass salt carex extract may be extracted from natural, hybrid or variety plants of green tea, and may be extracted from plant tissue cultures, and includes extracts extracted from parts of leaves, stems, roots, flowers and fruits, etc.
The Salicornia herbacea extract may include laminarin (laminarin) or fucoidan (fucoidan).
In the present invention, the term "laminarin" refers to a carbohydrate contained in the cell wall of brown algae, and is a hypotonic polysaccharide corresponding to starch of higher plants.
In the present invention, the term "fucoidan (fucoidan)" refers to a viscous polysaccharide contained in brown algae, which is a substance that binds basic sugar called Fucose (Fucose) and a sulfate group.
In the present invention, the term "prevention" refers to any action that inhibits or delays the onset of sarcopenia by administering a composition.
In the present invention, the term "treatment" refers to the amelioration or beneficial alteration of all behaviors of sarcopenia symptoms by administration of the composition.
Laminarin and fucoidan included in the pharmaceutical composition of the present invention can inhibit myostatin (myostatin) mRNA or protein expression and MURF1 (Muscle RING-finger protein-1) protein expression, and particularly can reduce an increase in myostatin expression caused by bleomycin treatment or UV stimulation (see fig. 1 to 3). The bleomycin (bleomycin) is an antitumor antibiotic used as an effective anticancer agent for squamous cell carcinoma or malignant lymphoma, etc., or is called an aging factor.
The pharmaceutical composition of the present invention can be prepared by a method known in the medical field to be used as a medicament, and mixed with a pharmaceutically acceptable carrier, excipient, diluent, stabilizer, preservative, etc., to be prepared and used in the form of powder, granule, tablet, capsule, injection, etc. Also, the composition may be prepared as a sustained-release preparation such that the release of the active ingredient (including a matrix for sustained-release purposes in addition to the active ingredient) occurs slowly.
The pharmaceutically acceptable carrier may further include, for example, a carrier for oral administration or a carrier for parenteral administration. Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid and the like. Also, it may include various drug delivery substances for oral peptide formulation. In addition, the carrier for parenteral administration may include water, suitable oil, saline, aqueous glucose, ethylene glycol, etc., and may further include a stabilizer and a preservative. Suitable stabilizers include antioxidants such as sodium bisulfite, sodium sulfite, ascorbic acid, or the like. Suitable preservatives may be benzalkonium chloride, methyl or propyl p-hydroxybenzoates and chlorobutanol. In addition to the above ingredients, the pharmaceutical composition of the present invention may further include lubricating agents, wetting agents, sweetening agents, flavoring agents, emulsifying agents, suspending agents and the like.
The diluent may be a non-aqueous solvent such as propylene glycol, polyethylene glycol, olive oil, vegetable oil such as peanut oil, or saline (preferably, 0.8% saline), or an aqueous solvent such as water containing a buffer medium (preferably, 0.05M phosphate buffer), but is not limited thereto.
The excipient may be starch, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, sodium stearate, glycerol monostearate, talc, sodium chloride, anhydrous skim milk, glycerol, propylene, glycol, water, ethanol, etc., but is not limited thereto.
The stabilizer may be a carbohydrate such as sorbitol, mannitol, starch, sucrose, dextran, glutamic acid, or glucose, or a protein such as milk powder, animal, plant, or microbial protein such as serum albumin or casein, but is not limited thereto.
The preservative may be thiomersal, merthiolate (merthiolate), gentamicin, neomycin, nystatin, amphotericin B, tetracycline, penicillin, streptomycin, and polymyxin B, but is not limited thereto.
The pharmaceutical compositions of the present invention may be administered to mammals, including humans, by any method, such as oral administration or parenteral administration. The parenteral administration method may be intravenous injection, intramuscular injection, intraarterial administration, intramedullary administration, intrathecal administration, transdermal administration, subcutaneous administration, intraperitoneal administration, intranasal administration, intestinal administration, topical administration, sublingual administration or rectal administration, but is not limited thereto.
The pharmaceutical composition of the present invention may be formulated for oral administration or parenteral administration according to the administration route as described above.
The total effective amount of the pharmaceutical composition of the present invention may be administered to a patient in a single dose (single dose) and may be administered by a split treatment regimen of multiple dose (multiple dose) long-term administration. The pharmaceutical composition of the present invention may vary the content of the active ingredient according to the severity of the disease. This can be determined in consideration of various factors such as formulation method, administration route and treatment frequency, and age, body weight, health condition, disease symptoms, administration time and method of the patient, etc. In view of these points, one skilled in the art will be able to determine an appropriate effective dose of the composition of the present invention. The pharmaceutical composition according to the present invention is not particularly limited in its dosage form, administration route and administration method as long as it exhibits the effects of the present invention.
According to another embodiment of the present invention, there is provided a food composition for preventing or improving sarcopenia, comprising an extract of salicornia herbacea as an active ingredient.
In the present invention, the term "improvement" refers to a parameter related to the treatment situation, for example, to all actions that at least reduce the extent of symptoms.
Further, when the food composition of the present invention is used as a food additive, the composition may be added as it is or may be used together with other foods or food ingredients, and may be suitably used according to a conventional method. Generally, when preparing a food or beverage, the composition of the present invention is added in an amount of 15% by weight or less, preferably 10% by weight or less, based on the raw materials. However, if it is ingested for a long period of time for health and hygiene or for the purpose of health control, it may be lower than the above range and there is no problem in safety, so the amount of active ingredient used may be higher than the above range.
The kind of the food is not particularly limited. Examples of foods to which the substance can be added include meats, sausages, breads, chocolates, candies, snacks, cookies, pizza, ramen, other noodles, chewing gums, dairy products including ice cream, various soups, beverages, teas, drinks, alcoholic beverages, vitamin complexes, and the like, and include all health foods in a general sense.
Hereinafter, the present invention will be described in more detail by way of examples. The following examples are merely illustrative of the present invention and the scope of the present invention is not limited thereto.
Example 1 verification of inhibitory Effect against sarcopenia caused by UV irradiation
C2C12 muscle precursor cells (ATCC, US) were cultured in DMEM containing 10% FBS. At this time, 3 × 10 5 Cells were seeded in a 60-pie culture dish. The next day after sowing, laminarin and fucoidan were treated separately and left for 1 hour. After 1 hour, the growth medium (10% fbs DMEM) was removed and washed with PBS. After removal of PBS, the plate cover was removed from the UV cross-linker (UVP CL-1000) and the process was carried out at 3J/m 2 UV irradiation (0 days). After 24 hours of culture in a CO2 Incubator (Incubator), the growth medium was removed in the same manner and PBS was washed, followed by 3J/m 2 UV irradiation (1 day).
The next day, harvesting was performed at the same time (2 days) and western blotting was used to detect changes in expression of myostatin and MURF1 proteins as target proteins in cell lysates that modulate muscle mass. Comparative analyses were performed using anti-GDF 8 (Genetex, GTX 32624) as myostatin, anti-MURF 1 antibody (Abcam, ab 172479) as MURF1, and β -actin antibody (ENOGene E12-041-4) as protein loading controls.
RNA was isolated using RNeasy-Mini kit (Qiagen, US), and after cDNA was synthesized using AMV Reverse Transcriptase (Promega, US), the degree of myostatin mRNA expression was confirmed by cDNA using PCR. The PCR conditions were performed in the following order: initial denaturation at 95 ℃ for 5 minutes, i) denaturation at 95 ℃ for 5 seconds, ii) annealing at 62.8 ℃ for 10 seconds, and iii) final extension at 72 ℃ for 10 minutes. The following primers were used to detect mRNA expression.
[ Table 1]
As a result, as shown in fig. 1 to 3, it was confirmed that the expression of myostatin and MURF1 increased by UV irradiation was decreased with the treatment of laminarin and fucoidan.
Example 2 verification of inhibitory Effect against sarcopenia caused by bleomycin
The C2C12 muscle precursor cells (ATCC, US) were cultured in DMEM containing 10% FBS. At this time, 3 × 10 5 Cells were seeded in a 60-cake dish, and after seeding, bleomycin (bleomycin) was treated and left for 1 hour.
Next, laminarin and fucoidan were treated separately and left for 1 hour, after which the growth medium (growth media) was removed (10% FBS DMEM) and washed with PBS. After washing, western blotting was used to detect changes in expression of myostatin and MURF1 proteins as target proteins in cell lysates that modulate muscle mass. Comparative analyses were performed using anti-GDF 8 (Genetex, GTX 32624) as myostatin and β -actin antibody (ENOGene E12-041-4) as protein loading controls.
RNA was isolated using RNeasy-Mini kit (Qiagen, US), and after cDNA was synthesized using AMV Reverse Transcriptase (Promega, US), the degree of myostatin mRNA expression was confirmed by cDNA using PCR. The PCR conditions were performed in the following order: initial denaturation at 95 ℃ for 5 minutes, i) denaturation at 95 ℃ for 5 seconds, ii) annealing at 62.8 ℃ for 10 seconds, and iii) final extension at 72 ℃ for 10 minutes. The same primers as described in example 1 were used to detect mRNA expression.
As a result, as shown in fig. 1 and 2, it was confirmed that the expression of myostatin, which was increased by bleomycin, was decreased by the treatment of laminarin and fucoidan.
From the results of the examples, it can be seen that laminarin and fucoidan components in the turfgrass salt horn extract can inhibit the expression of the indicative proteins myostatin and MURF1 associated with muscle mass regulation, thereby effectively preventing or treating sarcopenia.
In summary, the embodiments have been described with respect to a limited number of embodiments and drawings, and those skilled in the art will be able to make numerous modifications and variations to the above description. For example, the techniques described may be performed in a different order from the methods described, or the components described may be combined or combined in a different form from the methods described, or may be replaced or substituted with other components or equivalents, thereby obtaining the same effects.
Accordingly, other embodiments, examples, and equivalents to the scope of the claims are all within the scope of the claims.
Claims (1)
1. Use of laminarin for the preparation of a medicament for the prevention or treatment of sarcopenia.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2018-0084054 | 2018-07-19 | ||
| KR20180084054 | 2018-07-19 | ||
| KR10-2019-0086296 | 2019-07-17 | ||
| KR1020190086296A KR20200010084A (en) | 2018-07-19 | 2019-07-17 | Pharmaceutical composition for preventing or treating sarcopenia comprising Salicornia herbacea extract |
| PCT/KR2019/008942 WO2020017921A1 (en) | 2018-07-19 | 2019-07-19 | Pharmaceutical composition, for preventing or treating sarcopenia, containing salicornia europaea extract |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112739361A CN112739361A (en) | 2021-04-30 |
| CN112739361B true CN112739361B (en) | 2022-10-28 |
Family
ID=69322092
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980061359.0A Active CN112739361B (en) | 2018-07-19 | 2019-07-19 | Use of laminarin for preparing medicine for preventing or treating sarcopenia |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR20200010084A (en) |
| CN (1) | CN112739361B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20230045189A (en) | 2021-09-28 | 2023-04-04 | 동의대학교 산학협력단 | Composition for preventing or improving sarcopenia comprising rosemary extract as an active ingredient |
| KR20230045187A (en) | 2021-09-28 | 2023-04-04 | 동의대학교 산학협력단 | Composition for preventing or improving sarcopenia comprising herbal extract and brewer's yeast powder as active ingredients |
| KR20230045192A (en) | 2021-09-28 | 2023-04-04 | 동의대학교 산학협력단 | Composition for preventing or improving sarcopenia comprising lavender extract as an active ingredient |
| KR20230045186A (en) | 2021-09-28 | 2023-04-04 | 동의대학교 산학협력단 | Composition for preventing or improving sarcopenia comprising bean leaf extract as an active ingredient |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR100495767B1 (en) * | 2002-08-21 | 2005-06-16 | 주식회사 비피도 | Composition using as probiotic agent using Salicornia herbacea |
| CA2689445A1 (en) * | 2006-06-01 | 2007-12-06 | Sakura Properties, Llc | Fucoidan compositions and methods |
| KR100868261B1 (en) * | 2007-04-30 | 2008-11-11 | 한국식품연구원 | Composition having muscle strength activity |
-
2019
- 2019-07-17 KR KR1020190086296A patent/KR20200010084A/en not_active IP Right Cessation
- 2019-07-19 CN CN201980061359.0A patent/CN112739361B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN112739361A (en) | 2021-04-30 |
| KR20200010084A (en) | 2020-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112739361B (en) | Use of laminarin for preparing medicine for preventing or treating sarcopenia | |
| US10960040B2 (en) | Composition for preventing and treating muscle diseases or improving muscular function, containing platycodon grandiflorum extract | |
| KR101997060B1 (en) | Composition for prevention or treatment of muscular disorder, or improvement of muscular functions comprising fermented deer antler | |
| JP2019520319A (en) | Composition for improving muscle function or exercise performance including azuki bean | |
| KR102513923B1 (en) | Pharmaceutical composition for preventing or treating sarcopenia comprising Salicornia herbacea extract | |
| Park et al. | Kimchi and an active component, β-sitosterol, reduce oncogenic H-Rasv12-induced DNA synthesis | |
| KR20200138121A (en) | Pharmaceutical composition for preventing or treating glioblastoma comprising Phellodendron amurense Ruprecht or Scutellaria baicalensis | |
| KR102137388B1 (en) | Composition for preventing or treating cancer comprising fruit extracts of alnus sibirica or fraction thereof | |
| KR102332654B1 (en) | Pharmaceutical composition for preventing or treating sarcopenia comprising phytoncide | |
| KR20200083141A (en) | Compositions comprising extracts of Sophorae fructus and pomegranate for preventing or improving menopausal symptoms | |
| KR102487651B1 (en) | A composition for preventing, improving or treating sarcopenia comprising extracts of wheat sprout | |
| KR101803000B1 (en) | Pharmaceutical compositions for preventing or treating lung cancer comprising apigenin, curcumin, and honokiol as active ingredients | |
| KR20180050272A (en) | Composition for preventing or treating obesity comprising Chrysanthemum leaf | |
| KR100891881B1 (en) | Composition for preventing and treating hyperlipidemia and vascular disease due to highly activated MMP comprising 3,4,5-trihydroxybenzaldehyde as an active ingredient | |
| KR102122408B1 (en) | Composition for preventing, ameliorating or treating andropause syndrome comprising roasted Glycyrrhiza uralensis extract as effective component | |
| KR20200009543A (en) | Pharmaceutical composition for preventing or treating sarcopenia comprising eucalyptus extract | |
| KR20190118961A (en) | Composition for Preventing or Improving Muscle Atrophy Comprising Kukoamine A and Kukoamine B | |
| WO2020017915A1 (en) | Pharmaceutical composition comprising phytoncide for preventing or treating sarcopenia | |
| KR102561733B1 (en) | Composition for ameliorating blood circulation comprising extract of Capsicum annuum by-product as effective component | |
| KR102264593B1 (en) | Composition for preventing, improving or treating disease related with melanin depletion comprising extract of Vaccinium oldhamii | |
| US20220088106A1 (en) | Composition comprising cudrania tricuspidate as effective component for alleviating, treating, or preventing muscular diseases, or improving muscule functions | |
| KR20130094553A (en) | Food composition, pharmaceutical composition and animal medicine against cancer containing gingerenone a | |
| KR102197296B1 (en) | Pharmaceutical composition for preventing or treating lung cancer comprising extract of Schoenoplectus triqueter | |
| KR101924880B1 (en) | Composition for promoting differentiation of muscle cells containing Terminalia chebula extract as effective component | |
| KR20200010087A (en) | Pharmaceutical composition for preventing or treating sarcopenia comprising myokine |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |